Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000796880 | SCV000936413 | uncertain significance | not provided | 2025-01-18 | criteria provided, single submitter | clinical testing | This sequence change replaces leucine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 1135 of the MSH3 protein (p.Leu1135Arg). This variant is present in population databases (rs148947624, gnomAD 0.07%). This variant has not been reported in the literature in individuals affected with MSH3-related conditions. ClinVar contains an entry for this variant (Variation ID: 643220). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002460107 | SCV002618392 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-01-04 | criteria provided, single submitter | clinical testing | The p.L1135R variant (also known as c.3404T>G), located in coding exon 24 of the MSH3 gene, results from a T to G substitution at nucleotide position 3404. The leucine at codon 1135 is replaced by arginine, an amino acid with dissimilar properties. In one study, this alteration was identified in 1/1231 colorectal cancer cases and 0/93 controls (DeRycke MS et al. Mol Genet Genomic Med, 2017 Sep;5:553-569). This amino acid position is not well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Gene |
RCV000796880 | SCV002819091 | uncertain significance | not provided | 2022-07-08 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Baylor Genetics | RCV003467359 | SCV004197020 | uncertain significance | Endometrial carcinoma | 2023-11-21 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV005036145 | SCV005666224 | uncertain significance | Endometrial carcinoma; Familial adenomatous polyposis 4 | 2024-03-16 | criteria provided, single submitter | clinical testing |